Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Absci’s dense biotech disclosures can feel like parsing a lab notebook written in code. R&D capitalization rules, milestone accounting, and rapidly evolving regulatory language turn every 10-K into a puzzle. That’s why our SEC filings hub tackles the complexity head-on, turning “Absci insider trading Form 4 transactions” and clinical-stage risk factors into clear, decision-ready insights.
Need the latest numbers? Each Absci quarterly earnings report 10-Q filing is indexed the moment it posts to EDGAR, with AI-powered summaries highlighting cash runway, collaboration revenue swings, and pipeline spend. Material news breaks fast too—our platform pushes alerts and plain-English takeaways for every Absci 8-K material events explained entry, so you know exactly what changed and why.
Curious whether executives are buying ahead of data readouts? Track Absci Form 4 insider transactions real-time and dive deeper with Absci executive stock transactions Form 4 tables already totaled for you. Preparing a valuation model? The Absci annual report 10-K simplified section distills 200-plus pages into key financials, IP assets, and regulatory risks. Governance analysts can compare board pay with the Absci proxy statement executive compensation snapshot, while newcomers benefit from understanding Absci SEC documents with AI through concise, jargon-free briefs.
- AI summaries translate complex biotech language into investor-ready points.
- Real-time feeds cover every form—from 10-K to 8-K—for complete Absci earnings report filing analysis.
- Searchable database links each disclosure to the questions professionals actually ask.
Spend less time decoding filings and more time acting on insights—our platform turns Absci’s regulatory maze into a straight path.
On July 9, 2025, Kite Realty Group Trust (NYSE: KRG) submitted a Form 4 reporting that director Victor J. Coleman acquired 524 common share units on July 1, 2025. The units were recorded at a price of $0, indicating a routine equity grant awarded as part of director compensation. After the transaction, Coleman’s direct ownership stands at 96,425 KRG shares. No derivative securities were involved, and there is no indication of open-market buying or selling. The filing reflects a modest, non-cash increase in insider holdings and is not likely to materially affect Kite Realty Group’s share structure or market outlook.
Absci Corporation (NASDAQ: ABSI) filed an 8-K announcing the appointment of Mary Szela, current CEO, President and Director of Trisalus Life Sciences, to Absci’s Board of Directors effective July 7, 2025. Her addition expands the Board from six to seven members and creates a third Class III seat, with a term expiring at the 2027 annual meeting.
Under the company’s Non-Employee Director Compensation Policy, Ms. Szela will receive an initial stock option for 178,400 shares of common stock, priced at the NASDAQ closing price on the grant date. The option vests in equal monthly installments over three years and accelerates to full vesting upon a defined “Sale Event.” She will also earn a standard $40,000 annual cash retainer.
The filing confirms there are no related-party transactions, family relationships, or special arrangements tied to her selection, and Ms. Szela will sign Absci’s standard indemnification agreement. Other than this governance change, the 8-K contains no financial results or strategic transaction disclosures.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
What is the core business of Absci Corp?
How does Absci integrate AI into its drug discovery process?
What differentiates Absci from traditional drug discovery companies?
Who are some of Absci's key collaborators?
In which therapeutic areas is Absci active?
How does the Integrated Drug Creation™ platform benefit drug development?
What challenges does Absci face in the competitive biopharma landscape?
